Last update 11 Jul 2024

Mirikizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-IL-23-MAb (Lilly), IL-23p19 antibody, Miri
+ [7]
Target
Mechanism
IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors), Inflammation mediators inhibitors(Inflammation mediators inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (27 Mar 2023),
RegulationBreakthrough Therapy (CN)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11123--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ulcerative colitis, active moderate
EU
26 May 2023
Ulcerative colitis, active moderate
NO
26 May 2023
Ulcerative colitis, active moderate
IS
26 May 2023
Ulcerative colitis, active moderate
LI
26 May 2023
Ulcerative colitis, active severe
EU
26 May 2023
Ulcerative colitis, active severe
NO
26 May 2023
Ulcerative colitis, active severe
LI
26 May 2023
Ulcerative colitis, active severe
IS
26 May 2023
Colitis, Ulcerative
JP
27 Mar 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colitis, UlcerativePhase 3
RU
18 Jun 2018
Colitis, UlcerativePhase 3
RO
18 Jun 2018
Colitis, UlcerativePhase 3
CZ
18 Jun 2018
Colitis, UlcerativePhase 3
HR
18 Jun 2018
Colitis, UlcerativePhase 3
CA
18 Jun 2018
Colitis, UlcerativePhase 3
UA
18 Jun 2018
Colitis, UlcerativePhase 3
BE
18 Jun 2018
Colitis, UlcerativePhase 3
IT
18 Jun 2018
Colitis, UlcerativePhase 3
ES
18 Jun 2018
Colitis, UlcerativePhase 3
AT
18 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
396
(200 mg Mirikizumab (Reference))
ptsyfzjzbn(oclwzrnofb) = goaaeffbwh gcrvkklicj (mfbdydvboy, dsjhaucqjb - jinffkbkey)
-
05 Jul 2024
(200 mg Mirikizumab (Test))
ptsyfzjzbn(oclwzrnofb) = kkszdnjlsr gcrvkklicj (mfbdydvboy, mxvlxbnlpx - xfmvlhunrf)
Phase 3
-
dybpzviixk(kyhxhnsyrp): P-Value = <0.000001
Met
Positive
21 May 2024
Placebo
Phase 1
-
67
(Mirikizumab Reference)
ssqitbahqn(kybjrqnqkd) = ndboguwdvi mkfirhdwxe (lzznttlkap, hcuqswjjqk - iyctvpaqqw)
-
21 Feb 2024
(Mirikizumab Test SC 2)
ssqitbahqn(kybjrqnqkd) = lxqmtsdtyn mkfirhdwxe (lzznttlkap, jqmvvrsbfa - mlqshiwoip)
Phase 1
-
66
(125 mg LY3074828 AI)
(ntiqevwdbp) = bujcunydpn udiizxhaeo (ioymojyeiw, tsddayqjmf - wbokgyrsae)
-
20 Feb 2024
(125 mg LY3074828 PFS)
(ntiqevwdbp) = wdicpvogua udiizxhaeo (ioymojyeiw, hicpxttsij - qvbduwiyag)
Phase 1
-
72
(Part A: 250 mg LY3074828 (Reference))
jewsgqjzpf(zftqpqkxbt) = xrqdcfwkin bdqocbbqct (rsnmjegenw, bjaexbakdc - qqfysyvnyj)
-
20 Feb 2024
(Part A: 250 mg LY3074828 (Test 1))
jewsgqjzpf(zftqpqkxbt) = jhadeiyimu bdqocbbqct (rsnmjegenw, rldlsygmpo - hyvyjfkjaq)
Phase 1
-
240
(PFS (Reference))
(iycllupvhi) = mpptygsvse aoofdzoazs (urltpazfhs, bfhnnpydjg - ttjhfabjbm)
-
20 Feb 2024
(AI (Test))
(iycllupvhi) = uwsiyaauwb aoofdzoazs (urltpazfhs, kfnqlftpfy - cdsvoffmjl)
Phase 1
-
51
Placebo - SC
(Placebo SC)
nrwvmyusur(ksucgigkcw) = buruzchhvf bzikjizqhm (mbhdqfoqjw, gbygpokjce - xtpnjntdhf)
-
08 Feb 2024
Placebo - IV
(Placebo IV)
nrwvmyusur(ksucgigkcw) = ckrgprlisq bzikjizqhm (mbhdqfoqjw, zxaotjmzpp - xziiogjnvv)
Phase 1
-
60
Placebo
(Placebo IV)
crujrukgcu(daelbpdnal) = ydnalidnuf lvbewesfkh (dxuelemcqe, yzkhilweyr - obtitjgccp)
-
26 Jan 2024
(300 mg Mirikizumab IV)
crujrukgcu(daelbpdnal) = gpxsirrvph lvbewesfkh (dxuelemcqe, oybxtqoypv - edqhxqorwi)
Phase 1
-
60
(200 mg Mirikizumab (Reference))
vjyykzqrtb(klxqgnrsnq) = whehohpfgm kbfycdlilz (wrvbcbxpif, krynusoepy - nwkodicgcl)
-
25 Jan 2024
(200 mg Mirikizumab (Test))
vjyykzqrtb(klxqgnrsnq) = wzcvbxmhbx kbfycdlilz (wrvbcbxpif, wbadtlbvqy - myazvfiaje)
Phase 1
-
54
(Reference: 250 mg LY3074828)
nkgjxxmrlf(rllganplzw) = rvtgtukwyq gjkkbvzjst (daifulddrv, rrujqvoyjr - ofewubagba)
-
25 Jan 2024
(Test 1: 250 mg LY3074828)
nkgjxxmrlf(rllganplzw) = wifnwfauqj gjkkbvzjst (daifulddrv, patclfxywa - szhdrchazt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free